Radioimmunotherapy in Follicular Lymphoma: An Update

Joseph R. Mace, MD Florida Cancer Specialists Saint Petersburg, Florida H&O What are the traditional treatment options for follicular lymphoma (FL) patients? JM Treatment planning and […]

Gemtuzumab: Time to Bring Back on the Market?

James M. Foran, MD, FRCPC Associate Professor Division of Hematology & Medical Oncology Mayo Clinic Cancer Center Jacksonville, Florida H&O What is gemtuzumab ozogamicin? JF Gemtuzumab […]

Inotuzumab: The Most Active Single Agent in Acute Lymphoblastic Leukemia?

Deborah A. Thomas, MD Associate Professor Department of Leukemia Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston, Texas H&O What is inotuzumab […]

Risk of Early Death in Multiple Myeloma

Shaji Kumar, MD Associate Professor Division of Hematology Mayo Clinic Rochester, Minnesota H&O What are the survival outcomes following diagnosis of multiple myeloma? SK Survival has […]

Ruxolitinib: The First Agent Approved for Myelofibrosis

Srdan Verstovsek, MD, PhD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston, Texas H&O What is […]

Burkitt Lymphoma: Analysis of the Genome

Sandeep Dave, MD, MBA Assistant Professor Duke Institute for Genome Sciences and Policy Duke Cancer Institute Department of Medicine/Oncology Division Duke University Durham, North Carolina H&O What […]

Ponatinib: Targeting the T315I Mutation in Chronic Myelogenous Leukemia

Neil P. Shah, MD, PhD Associate Professor Division of Hematology/Oncology Co-Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center Edward A. Ageno Distinguished Professor University […]

JAK2 Inhibitors in Myelofibrosis

Animesh Pardanani, MBBS, PhD Assistant Professor of Medicine Mayo Clinic Rochester, Minnesota H&O What is myelofibrosis (MF)? AP MF is a BCR-ABL1-negative, chronic myeloproliferative neoplasm (MPN). It is […]

Blinatumomab: A Novel Agent to Treat Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

Anjali S. Advani, MD Director, Inpatient Leukemia Unit Cleveland Clinic Lerner College of Medicine Department of Hematologic Oncology and Blood Disorders The Cleveland Clinic Cleveland, Ohio […]

Optimal Timing for Transplant in Multiple Myeloma

S. Vincent Rajkumar, MD Professor of Medicine Mayo Clinic Rochester, Minnesota H&O What are the current forms of available transplant, and how do they affect patient […]

B-Cell Receptor Inhibitors in Chronic Lymphocytic Leukemia

Ian W. Flinn, MD, PhD Director Hematologic Malignancies Research Sarah Cannon Research Institute Nashville, TN H&O What is the current standard of care for chronic lymphocytic leukemia […]

Mixed-Phenotype Acute Leukemia: Disease Features and Outcome

Estella Matutes, MD Reader/Consultant Hematologist Section of Haemato-Oncology Institute of Cancer Research London, England H&O Can you provide some background on mixed-phenotype acute leukemia (MPAL)? EM MPAL is […]

Survival After Relapse in Childhood Acute Lymphoblastic Leukemia

Nita L. Seibel, MD Head of Pediatric Solid Tumor Therapeutics Clinical Investigations Branch Cancer Therapy Evaluation Program The National Cancer Institute Bethesda, Maryland H&O Could you discuss […]

JAK2 Inhibitors in Polycythemia Vera

Alfonso Quintás-Cardama, MD Assistant Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas H&O What is polycythemia vera […]

A New Formulation of Vincristine for Acute Lymphoblastic Leukemia

Leonard Heffner, Jr, MD Associate Professor of Hematology and Oncology The Emory Clinic Atlanta, Georgia H&O How has conventional vincristine been used in the treatment of acute […]

Lenalidomide in CLL: What Is the Optimal Dose?

Clemens M. Wendtner, MD Professor of Medicine Deputy Director of Department I of Internal Medicine (Hem/Onc) Head of the Laboratory of Molecular Biology and Immunology of CLL […]

Hypomethylating Agents in Myelodysplastic Syndromes

William G. Blum, MD Associate Professor College of Medicine The Ohio State University Comprehensive Cancer Center Columbus, Ohio H&O What are myelodysplastic syndromes (MDS)? WB The term describes […]

Omacetaxine: The FDA Decision

Ellin Berman, MD Attending Physician Leukemia Service Division of Hematologic Oncology Memorial Sloan-Kettering Cancer Center New York, New York H&O Could you provide some background on omacetaxine? […]

Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, MD, PhD Internal Medicine III University of Ulm Ulm, Germany H&O What characteristics predict outcome in chronic lymphocytic leukemia (CLL)? SS CLL is usually a disease […]

Advances in CML: The Role of Allogeneic Hematopoietic Stem Cell Transplantation

Borje S. Andersson, MD Professor Department of Stem Cell Transplantation Division of Cancer Medicine University of Texas M.D. Anderson Cancer Center Houston, Texas H&O What is the […]